Literature DB >> 15037670

Practical considerations in the use of apomorphine injectable.

Annette Bowron1.   

Abstract

This manuscript provides a practical summary of guidelines for institution of apomorphine subcutaneous injectable therapy, including patient education, pre-treatment issues, dosage titration and side-effect care. The timing of each injection is crucial if an impending "off" period is to be averted. Patients need to be aware of symptoms of an approaching "off" period, and the injection should be administered at the onset or ideally, in anticipation of an "off" episode. Patients being considered for apomorphine treatment should undergo pre-treatment assessment and optimization of ongoing oral therapy prior to initiation. Education and counseling regarding the benefits of apomorphine can often alleviate this. In addition, and where available, it is beneficial to provide the patient and caregiver(s) with additional written information and videos provided by the manufacturer demonstrating the operation of the pump or pen injection systems. Once a patient has been assessed as being a suitable candidate for apomorphine, an apomorphine challenge is performed to determine responsiveness and guide appropriate dosing, establish an individual dose, and to observe for side effects, such as nausea, postural hypotension, excessive somnolence, or dyskinesia. Three days prior to the challenge, domperidone 20 mg tid or trimethobenzamide (Tigan) 300 mg tid is recommended. Potential side effects include yawning, dopaminergic side effects, such as dyskinesias, nausea, orthostatic hypotension, confusion, hallucinations, somnolence and rarely, hypersexuality or other behavioral disturbances, and skin nodule formation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037670     DOI: 10.1212/wnl.62.6_suppl_4.s32

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  The utility of (11)C-arachidonate PET to study in vivo dopaminergic neurotransmission in humans.

Authors:  Madhav Thambisetty; Kathy A Gallardo; Jeih-San Liow; Lori L Beason-Held; John C Umhau; Abesh K Bhattacharjee; Margaret Der; Peter Herscovitch; Judith L Rapoport; Stanley I Rapoport
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-14       Impact factor: 6.200

Review 2.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

3.  Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-12

Review 4.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 5.  Role of apomorphine in the treatment of Parkinson's disease.

Authors:  Allison Boyle; William Ondo
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 6.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

7.  Patient Preferences for Treating "OFF" Episodes in Parkinson's Disease: A Discrete Choice Experiment.

Authors:  Andrew Thach; Jessie Sutphin; Joshua Coulter; Colton Leach; Eric Pappert; Carol Mansfield
Journal:  Patient Prefer Adherence       Date:  2021-06-01       Impact factor: 2.711

8.  Dopamine transporter single-photon emission computerized tomography supports diagnosis of akinetic crisis of parkinsonism and of neuroleptic malignant syndrome.

Authors:  G Martino; M Capasso; M Nasuti; L Bonanni; M Onofrj; A Thomas
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

Review 9.  Treatment of Parkinson's disease in the advanced stage.

Authors:  C Ossig; H Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2013-03-10       Impact factor: 3.575

10.  Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease.

Authors:  Luca Passamonti; Maria Salsone; Nicola Toschi; Antonio Cerasa; Marco Giannelli; Carmelina Chiriaco; Giuseppe Lucio Cascini; Francesco Fera; Aldo Quattrone
Journal:  Brain Behav       Date:  2013-03-22       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.